Novo Nordisk A/S $NVO Shares Sold by Smith Chas P & Associates PA Cpas

Smith Chas P & Associates PA Cpas lessened its position in Novo Nordisk A/S (NYSE:NVO) by 99.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 6,452 shares of the company’s stock after selling 943,699 shares during the period. Smith Chas P & Associates PA Cpas’ holdings in Novo Nordisk A/S were worth $251,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Novo Nordisk A/S by 2,414.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock valued at $14,280,000 after buying an additional 286,034 shares during the period. Trust Co. of Vermont purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $1,250,000. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $2,324,000. Myriad Asset Management Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $1,846,000. Finally, Tevis Investment Management raised its stake in Novo Nordisk A/S by 65.7% in the first quarter. Tevis Investment Management now owns 74,090 shares of the company’s stock worth $2,813,000 after buying an additional 29,390 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $39.10 on Thursday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a market cap of $174.58 billion, a P/E ratio of 9.56, a PEG ratio of 1.34 and a beta of 0.76. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The firm has a fifty day moving average price of $42.21 and a 200 day moving average price of $44.01.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The firm had revenue of $11.98 billion during the quarter. Sell-side analysts predict that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 20.05%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. DZ Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, August 6th. UBS Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Berenberg Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $59.44.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced an average 25% reduction in body weight after 68 weeks among women with obesity or overweight in a late-stage analysis. The result strengthens the drug’s potential as a successor to Wegovy and could improve Novo’s long-term position in the expanding obesity-treatment market. Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis
• Positive Sentiment: The CagriSema data prompted a recent rally as investors viewed the treatment’s efficacy as a potential catalyst for renewed growth. Regulatory submissions and further clinical progress could provide additional upside, although approval is not yet guaranteed. Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
• Positive Sentiment: Novo expanded its 2026 share buyback, increasing its treasury-share stake to 1.2%. The program signals management’s confidence and may support earnings per share by reducing the number of shares outstanding. Novo Nordisk expands 2026 share buyback
• Neutral Sentiment: Novo remains a major player in diabetes and obesity treatments, with additional pipeline projects and partnerships offering potential growth over the next decade. However, those benefits depend on successful trials, regulatory approvals, manufacturing investment, and commercialization. Where Will Novo Stock Be in 10 Years?
• Negative Sentiment: Investors continue to assess rising competition from Eli Lilly and Viking Therapeutics, along with risks from drug-pricing pressure, intellectual-property challenges, and declining earnings estimates. These concerns help explain why the stock remains under pressure despite the promising CagriSema results. How Investors May Respond To Novo Nordisk Obesity Drug Competition

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.